Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Editas Medicine to Present at Investor Conferences in March

EDIT

CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March.  Details of the presentations are as follows:

Cowen & Company 37th Annual Healthcare Conference
Date:     Monday, March 6, 2017
Time:     2:40 p.m. ET
Location:     Boston
       
Barclays Global Healthcare Conference 2017
Date:     Thursday, March 16, 2017
Time:     9:30 a.m. ET
Location:     Miami

Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.  Archived replays will be available for approximately 30 days following the respective presentations.

About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Media Contact Dan Budwick
 Pure Communications, Inc.
 (973) 271-6085 dan@purecommunicationsinc.com Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 mark.mullikin@editasmed.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today